Lavestra Hct

Losartan potassium and hydrochlorothiazide, the active ingredients in Lavestra Hct, are an angiotensin II receptor blocker and a thiazide diuretic presented as an oral tablet for systemic use. They treat hypertension in adult patients.

GNH USA supplies Lavestra Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lavestra Hct combines an angiotensin II receptor blocker with a thiazide diuretic and is indicated for conditions related to elevated blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension. - Essential hypertension: helps achieve target blood pressure when monotherapy is insufficient. - High blood pressure: provides additive blood‑pressure control through dual mechanisms.

Lavestra Hct may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angioedema - Liver enzyme elevation - Blood dyscrasias (e.g., agranulocytosis)

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

- Renal impairment: assess kidney function and adjust therapy as needed. - Electrolyte balance: monitor serum potassium and sodium levels regularly. - Hepatic disease: use with caution in patients with liver dysfunction. - Pregnancy: avoid use unless clearly indicated by a physician. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lavestra Hct can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - ACE inhibitors or ARBs combined with aliskiren in diabetes: increased renal risk. - NSAIDs: may reduce antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Lithium: thiazide component can raise lithium levels. - Antidiabetic agents: may require dose adjustment due to blood‑pressure changes. - CYP2C9 inhibitors (e.g., fluconazole): can increase losartan exposure.